Indivior converts William Todd Horich’s equity awards

Converted awards remain subject to substantially the same terms, with merger-related restricted stock units vesting 40% at closing and 15% on each of four anniversaries.

Available on EDGAR 11/04/2026 - 06:06 PM EST Accepted by SEC EDGAR 11/04/2026 - 06:06 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. (INDV) assumed and converted outstanding Supernus Pharmaceuticals equity awards held directly by William Todd Horich, SVP, Chief Commercial Officer, at the merger’s effective time on November 2, 2026; Indivior was renamed Supernus, Inc. The conversion used a 1.5401 exchange ratio: award share counts were multiplied by the ratio and rounded down, while option exercise prices were divided by it and rounded up to the nearest cent. Converted awards remain subject to substantially the same terms, including vesting, except performance stock unit awards became time-vesting restricted stock units. A listed award of 154,010 restricted stock units vests 40% at closing and 15% on each of the four following anniversaries.

Insider Trade Summary

Other: 406,772 shares

Other 19 txns

Insider Horich William Todd

Role SVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Other	Employee Stock Option (right to buy) F1, F2	20,021	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	21,561	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	26,181	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	27,721	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	30,802	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	38,502	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	30,802	$0.00	$0.00
Other	Employee Stock Option (right to buy) F1, F2	20,791	$0.00	$0.00
Other	Restricted Stock Units F1, F3	9,625	$0.00	$0.00
Other	Restricted Stock Units F1, F4	3,850	$0.00	$0.00
Other	Restricted Stock Units F1, F5	5,197	$0.00	$0.00
Other	Restricted Stock Units F1, F6	4,620	$0.00	$0.00
Other	Restricted Stock Units F1, F7	154,010	$0.00	$0.00
Other	Restricted Stock Units F1, F8	1,155	$0.00	$0.00
Other	Restricted Stock Units F1, F8	2,695	$0.00	$0.00
Other	Restricted Stock Units F1, F8	3,850	$0.00	$0.00
Other	Restricted Stock Units F1, F9	808	$0.00	$0.00
Other	Restricted Stock Units F1, F9	1,886	$0.00	$0.00
Other	Restricted Stock Units F1, F9	2,695	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 216,381 contracts (Direct); Restricted Stock Units — 190,391 contracts (Direct)

Footnotes (9)

1. F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.
2. F2. The option vests in four equal annual installments beginning on the specified date.
3. F3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
4. F4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
5. F5. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
6. F6. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
7. F7. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
8. F8. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.
9. F9. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2028.

Key Figures

Exchange ratio: 1.5401 Converted option award: 38,502 common shares Option exercise price: $18.15 per share +2 more

5 metrics

Exchange ratio 1.5401 Applied to outstanding Supernus Pharmaceuticals equity awards converted at the merger’s effective time

Converted option award 38,502 common shares Exercise price of $18.15 per share; transaction dated November 2, 2026

Option exercise price $18.15 per share Option award covering 38,502 common shares

Restricted stock units 154,010 shares Merger-related award with vesting tied to closing and four anniversaries

Merger-related RSU vesting 40% at closing; 15% on each of four anniversaries Five-installment vesting schedule

Key Terms

exchange ratio, vesting, time-vesting restricted stock units, effective time

4 terms

exchange ratio technical

"multiplied by the 1.5401 exchange ratio"

The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.

vesting technical

"including vesting, that applied immediately prior to the effective time"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

time-vesting restricted stock units technical

"converted into time-vesting restricted stock units"

effective time technical

"at the effective time of the merger"

The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How were William Todd Horich’s equity awards converted in the INDV merger?

At the merger’s effective time on November 2, 2026, outstanding Supernus Pharmaceuticals equity awards were assumed by Indivior, renamed Supernus, Inc., and automatically converted into corresponding awards covering Supernus, Inc. shares using the 1.5401 exchange ratio.

How do the 154,010 merger-related RSUs vest?

The 154,010 restricted stock units vest in five installments: 40% at the merger closing, followed by 15% on each of the first, second, third and fourth anniversaries of closing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horich William Todd

(Last) (First) (Middle)

C/O SUPERNUS, INC., 9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Supernus, Inc. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$25.59	11/02/2026		J(1)		20,021		02/14/2019(2)	02/14/2028	Common Stock	20,021	$0.00	20,021	D
Employee Stock Option (right to buy)	$23.87	11/02/2026		J(1)		21,561		02/22/2020(2)	02/22/2029	Common Stock	21,561	$0.00	21,561	D
Employee Stock Option (right to buy)	$19.23	11/02/2026		J(1)		26,181		02/19/2022(2)	02/19/2031	Common Stock	26,181	$0.00	26,181	D
Employee Stock Option (right to buy)	$20.91	11/02/2026		J(1)		27,721		02/22/2023(2)	02/22/2032	Common Stock	27,721	$0.00	27,721	D
Employee Stock Option (right to buy)	$25.07	11/02/2026		J(1)		30,802		02/23/2024(2)	02/23/2033	Common Stock	30,802	$0.00	30,802	D
Employee Stock Option (right to buy)	$18.15	11/02/2026		J(1)		38,502		02/22/2025(2)	02/22/2034	Common Stock	38,502	$0.00	38,502	D
Employee Stock Option (right to buy)	$21.77	11/02/2026		J(1)		30,802		02/19/2026(2)	02/19/2035	Common Stock	30,802	$0.00	30,802	D
Employee Stock Option (right to buy)	$32.6	11/02/2026		J(1)		20,791		02/18/2027(2)	02/18/2036	Common Stock	20,791	$0.00	20,791	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		9,625		02/23/2024(3)	(3)	Common Stock	9,625	$0.00	9,625	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		3,850		02/22/2025(4)	(4)	Common Stock	3,850	$0.00	3,850	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		5,197		02/19/2026(5)	(5)	Common Stock	5,197	$0.00	5,197	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		4,620		02/18/2027(6)	(6)	Common Stock	4,620	$0.00	4,620	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		154,010		11/02/2026(7)	(7)	Common Stock	154,010	$0.00	154,010	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		1,155		12/31/2026(8)	(8)	Common Stock	1,155	$0.00	1,155	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		2,695		12/31/2026(8)	(8)	Common Stock	2,695	$0.00	2,695	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		3,850		12/31/2026(8)	(8)	Common Stock	3,850	$0.00	3,850	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		808		12/31/2028(9)	(9)	Common Stock	808	$0.00	808	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		1,886		12/31/2028(9)	(9)	Common Stock	1,886	$0.00	1,886	D
Restricted Stock Units	$0.00	11/02/2026		J(1)		2,695		12/31/2028(9)	(9)	Common Stock	2,695	$0.00	2,695	D

Explanation of Responses:

1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.

2. The option vests in four equal annual installments beginning on the specified date.

3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

5. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.

6. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

7. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.

8. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.

9. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2028.

	/s/ Timothy C. Dec, as attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)